Pheochromocytoma: Symptoms, Diagnosis, Survival, and Treatment

What is Pheochromocytoma?

Pheochromocytoma is a rare tumor originating from the adrenal gland, specifically from specialized hormone-secreting cells called chromaffin cells in the adrenal medulla.

In the general population, the incidence is approximately 2 cases per million people per year, and the tumor accounts for 1 in every 1,000 cases of hypertension, making it an uncommon but important and potentially treatable cause of high blood pressure. The hypertension is caused by continuous or intermittent release of catecholamines (epinephrine and norepinephrine) by the tumor.

The Classic Clinical Triad

Patients with pheochromocytoma classically present with a sudden-onset triad of three symptoms:

1. Headache,
2. Sweating,
3. Palpitations (awareness of rapid heartbeat).

Pheochromocytoma should always be considered in patients presenting with this triad, though in the majority of cases, appropriate diagnostic workup will exclude the diagnosis.

Why Recognition Matters

Identifying pheochromocytoma is particularly important because:

• It is curable in most cases (surgical resection is usually curative),
• It can occasionally be malignant (approximately 10% of cases)
• It can be part of hereditary cancer syndromes, such as Multiple Endocrine Neoplasia (MEN) and other genetic conditions
• Unrecognized pheochromocytoma carries serious risks during surgical procedures, physical stress, or pregnancy

Incidentaloma

In approximately 4% of cases, pheochromocytoma is discovered incidentally during imaging studies like CT or MRI. These scans are often performed for entirely unrelated reasons, such as trauma evaluation. This is termed an incidentaloma (a tumor discovered by accident).

Demographics and Overall Prognosis

• The tumor affects men and women equally,
• It is most common between 40 and 50 years of age (though any age can be affected, including children),
• 90% of cases are benign and surgically curable, with a 5-year survival rate exceeding 95%.

Adrenal Gland Anatomy

The adrenal glands, also called suprarenal glands, are two small endocrine glands. Each is positioned directly above one kidney: one above the right kidney and one above the left.

• Weight: 4–6 grams each,
• Shape: pyramidal or triangular.

Each adrenal gland is composed of two distinct, functionally different regions:

The adrenal medulla, the region where pheochromocytoma originates, produces catecholamines. These essential hormones allow the body to respond rapidly to acute stressors, triggering the “fight or flight” response. They regulate:

• Cardiac activity (heart rate and force of contraction),
• Blood vessel tone (vasoconstriction/vasodilation),
• Body temperature regulation,
• Metabolism of fats and glucose,
• Fluid and electrolyte balance,
• Interactions with other organ systems (brain, thyroid, pancreas, stomach, heart).

When the adrenal gland malfunctions and produces either too much or too little hormone, various disorders can develop. These include pheochromocytoma.

---

Causes

Cellular Origin

Pheochromocytoma develops from chromaffin cells, which are specialized neuroendocrine cells in the adrenal medulla. These cells derive embryologically from neural crest progenitor cells (sympathogonia) during fetal development. In fetal life, they are widely distributed throughout the body; after birth, the majority undergo apoptosis, with the remainder forming:

• The adrenal medulla (the predominant location in adults).
• Small clusters of extra-adrenal paraganglia, including the para-aortic ganglia (the organ of Zuckerkandl), the mediastinum, and the abdomen.

When chromaffin cells develop abnormalities in their structure or reproductive regulation, they can lead to pheochromocytoma. This condition may occur within the adrenal gland, known as adrenal pheochromocytoma, or, less frequently, in extra-adrenal locations (paraganglioma).

Tumor Behavior

The pheochromocytoma retains and amplifies the secretory function of the chromaffin cells from which it arises. It produces and releases:

• Catecholamines: epinephrine (adrenaline) and norepinephrine (noradrenaline),
• Catecholamine metabolites,
• Various peptide and non-peptide vasoactive substances.

All of these exert powerful effects on blood pressure and cardiovascular function.

Genetic Causes and Hereditary Syndromes

A significant proportion of pheochromocytomas have a hereditary basis. Current estimates suggest that 30–40% of all pheochromocytomas are associated with germline mutations in predisposing genes. The most clinically important are:

In hereditary cases, pheochromocytoma may:

• Be the sole clinical manifestation of the syndrome,
• Occur at a younger age than sporadic cases,
• Be bilateral (both adrenal glands affected) more frequently.

Important: Genetic testing for germline mutations is recommended for all patients diagnosed with pheochromocytoma, regardless of family history. This is because up to 25% of apparently sporadic cases carry a germline mutation.

---

Symptoms

Pheochromocytoma can manifest in two main patterns:

• Paroxysmal form: sudden, intense episodic attacks, often separated by symptom-free intervals,
• Persistent form: continuous, sustained symptoms without acute attacks.

Approximately half of all patients experience paroxysmal hypertensive attacks, which are episodes of sudden and severe blood pressure elevation. These attacks are accompanied by the classic triad.

The Classic Symptom Triad

1. Headache is severe and often throbbing. It occurs in up to 90% of symptomatic patients.
2. Sweating (diaphoresis) refers to excessive, widespread perspiration that goes beyond normal bodily cooling. This condition can occur unexpectedly or persist over time, often affecting daily activities.
3. Palpitations refer to the sensation of a rapid or forceful heartbeat.

Additional Symptoms

Accompanying symptoms may include:

• Anxiety and feelings of impending doom,
• Tremors,
• Abdominal pain,
• Chest pain,
• Fatigue and prostration after episodes,
• Nausea and vomiting,
• Shortness of breath,
• Visual disturbances,
• Dizziness and vertigo.

What Triggers an Attack?

Paroxysmal crises can be precipitated by:

• Emotional stress or anxiety,
• Physical compression of the tumor (causing abrupt catecholamine release):
  • Exercise,
  • Change of body position,
  • Large meals,
  • Defecation,
• Certain medications that can trigger catecholamine release:
  • Metoclopramide,
  • Sulpiride,
  • Corticosteroids,
  • Opioids,
  • Histamine,
  • Glucagon,
  • Tricyclic antidepressants.

The Typical Course of a Paroxysmal Attack

The attack often begins with a sensation of chest pressure or difficulty breathing, followed abruptly by:

• Severe headache.
• Tachycardia.
• Pallor of the skin (vasoconstriction).
• Cold, diaphoretic (sweaty) extremities: This condition results from catecholamine-induced peripheral vasoconstriction, mediated by α-receptors, and cardiac stimulation, mediated by β1-receptors. These effects significantly raise blood pressure and cardiac output.

If the attack is prolonged, additional symptoms develop:

• Nausea and vomiting,
• Visual disturbances,
• Abdominal and chest pain.

After the episode resolves, the patient typically experiences marked fatigue and prostration.

Symptoms of the Persistent Form

In sustained (non-paroxysmal) pheochromocytoma:

• Heat intolerance.
• Persistent hypertension with superimposed episodes of orthostatic hypotension (blood pressure drop upon standing).
• Unexplained weight loss.
• Elevated blood glucose (hyperglycemia) occurs because catecholamines stimulate glycogenolysis and gluconeogenesis.

---

Complications

Pheochromocytoma can cause serious complications affecting multiple organ systems, predominantly through the effects of sustained or intermittent severe hypertension:

Cardiovascular Complications

• Myocarditis (catecholamine-induced direct myocardial toxicity).
• Ischemic heart disease, which includes conditions like angina or myocardial infarction.
• Congestive heart failure.
• Cardiac arrhythmias.
• Cardiogenic shock.

Renal Complications

• Hypertensive nephropathy,
• Renal failure.

Ophthalmological Complications

• Hypertensive retinopathy (damage to retinal blood vessels from chronic high blood pressure).

Special Populations

Pregnancy: Unrecognized and untreated pheochromocytoma during pregnancy carries a dramatically elevated risk of maternal and fetal mortality. It represents one of the most dangerous endocrine emergencies in obstetrics.

Children: Pediatric pheochromocytoma is more frequently:

• Familial (genetic),
• Multiple (bilateral or multifocal),
• Extra-adrenal (paraganglioma).

---

Diagnosis

The physician should suspect pheochromocytoma based on:

• The characteristic symptom triad (headache, sweating, palpitations),
• Resistant or paroxysmal hypertension,
• Known family history of pheochromocytoma or associated genetic syndromes,
• Incidental adrenal mass found on imaging,
• Medications that may precipitate attacks.

Biochemical Diagnosis: Catecholamines and Metabolites

The biochemical cornerstone of pheochromocytoma diagnosis is the measurement of catecholamines and their metabolites in urine or plasma:

Urine Tests

• 24-hour urinary catecholamines (epinephrine + norepinephrine): values > 250 µg/24h are highly suggestive (normal ≤ 120 µg/24h).
• 24-hour urinary metanephrines and normetanephrines: particularly elevated in large tumors, and currently considered the most sensitive urine test.
• 24-hour urinary vanillylmandelic acid (VMA): more elevated in malignant forms; lower sensitivity than metanephrines.

Plasma Tests

In the paroxysmal form, 24-hour urine collection during symptom-free periods may yield normal results. In these cases:

• Urine samples collected during and immediately after a symptomatic episode are highly informative.
• Plasma catecholamines (collected during symptoms): epinephrine > 50 pg/mL and/or norepinephrine > 300 pg/mL support the diagnosis.
• Plasma metanephrines: currently the most sensitive blood test for pheochromocytoma, recommended as first-line biochemical screening.

Clonidine Suppression Test

The clonidine suppression test is still used in selected cases. Clonidine (0.3 mg orally) normally reduces plasma catecholamine levels in healthy individuals through central sympathetic inhibition. In patients with pheochromocytoma, catecholamine release is autonomous. Because it fails to suppress after clonidine administration, this confirms the diagnosis. Older provocative tests (historically used to provoke catecholamine release) are now essentially abandoned due to high false-positive rates and patient safety concerns.

Anatomical Localization: Imaging

Once biochemical testing confirms the diagnosis, imaging is required to localize the tumor (location, number, and size):

• CT scan (computed tomography): first-line imaging modality. It has excellent sensitivity for adrenal tumors larger than 1 cm and high spatial resolution.
• MRI (Magnetic Resonance Imaging): preferred in children, pregnant women, patients with iodine contrast allergy, or when extra-adrenal location is suspected; pheochromocytomas show characteristic bright signal on T2-weighted sequences.
• MIBG scintigraphy (meta-iodobenzylguanidine labeled with radioactive iodine-123 or iodine-131): functional imaging that identifies chromaffin tissue by its catecholamine uptake mechanism. It is particularly valuable for detecting extra-adrenal tumors, multiple lesions, and metastases.
• PET scan (particularly 18F-FDOPA PET or 68Ga-DOTATATE PET): reserved for specific clinical situations, including suspected malignant or metastatic disease and MIBG-negative tumors.

Differential Diagnosis

Many conditions, some common and some rare, can produce symptoms mimicking pheochromocytoma:

• Essential hypertension (all types),
• Anxiety disorders and panic attacks are among the most common mimickers,
• Hyperthyroidism,
• Paroxysmal supraventricular tachycardia,
• Vasomotor (migraine-type) headache,
• Anginal episodes,
• Hypoglycemic episodes (sweating, palpitations, tremors),
• Carcinoid syndrome (flushing, diarrhea, palpitations),
• Brain tumors causing autonomic symptoms,
• Menopause (hot flushes, palpitations, sweating),
• Epilepsy (autonomic seizures).

Because these conditions are far more prevalent than pheochromocytoma, they are often considered first, which can occasionally lead to diagnostic delays.

---

Treatment

Surgery: The Treatment of Choice

Surgical resection is the definitive treatment for pheochromocytoma and is curative in the majority of benign cases. Successful management requires multidisciplinary coordination among:

• Endocrinologists/internists (pre-operative medical preparation),
• Experienced anesthesiologists (management of intraoperative hemodynamic instability),
• Surgeons specializing in adrenal surgery.

Surgical approaches:

• Laparoscopic adrenalectomy: the preferred minimally invasive approach for most unilateral adrenal pheochromocytomas ≤ 6–8 cm. It is associated with shorter hospitalization and faster recovery.
• Open (trans-abdominal) adrenalectomy: required for large tumors (> 6–8 cm), malignant or invasive tumors, or when laparoscopic approach is not feasible.

Both adrenal glands and peri-aortic sympathetic ganglia must be carefully explored intraoperatively to rule out bilateral or extra-adrenal disease.

Post-resection: Following tumor removal, blood pressure characteristically drops to approximately 90/60 mmHg due to sudden elimination of excess catecholamines. The patient receives:

• IV fluid resuscitation (normal saline, colloids),
• Blood or plasma transfusion if needed, to restore circulating volume. Blood pressure returns to normal levels within days.

Important: If blood pressure does not fall after tumor removal, a second pheochromocytoma must be actively suspected and sought.

Bilateral adrenalectomy: When both adrenal glands must be removed, patients will require lifelong corticosteroid replacement therapy (hydrocortisone ± fludrocortisone), as the body can no longer produce its own cortisol and aldosterone.

Mandatory Pre-Operative Medical Preparation

α-adrenergic receptor blockade must be established before surgery to prevent potentially fatal intraoperative hypertensive crises caused by tumor manipulation:

• Phenoxybenzamine (non-selective, irreversible α-blocker): the traditional choice, started 1–3 weeks before surgery,
• Doxazosin (selective α1-blocker): increasingly preferred due to fewer side effects,
• Labetalol (combined α- and β-blocker): an alternative.

β-blockers (e.g., propranolol) may be added only after adequate α-blockade has been established to control tachycardia and arrhythmias.

Critical safety principle: β-blockers must NEVER be administered before α-blockade in pheochromocytoma. Doing so blocks β-mediated vasodilation while leaving α-mediated vasoconstriction unopposed, precipitating a severe, potentially fatal hypertensive crisis.

Management of Acute Hypertensive Crisis

If a pheochromocytoma crisis occurs (severe acute hypertension):

• First-line: Phentolamine (α-blocker), administered slowly by IV infusion with continuous blood pressure monitoring.
• Alternatives (when phentolamine is unavailable):
  • Urapidil: IV infusion
  • Nifedipine: oral drops

Treatment of Malignant or Metastatic Pheochromocytoma

When surgical resection is not possible (unresectable or metastatic disease):

• Radiometabolic therapy with high-dose 131I-MIBG (iodine-131 meta-iodobenzylguanidine): exploits the same catecholamine uptake mechanism as diagnostic MIBG scintigraphy to deliver targeted radiation to tumor cells. Response rates of 30–40%,
• Chemotherapy: the CVD regimen (cyclophosphamide, vincristine, dacarbazine) is the most established chemotherapy protocol for malignant pheochromocytoma,
• Somatostatin analogue-based PRRT (peptide receptor radionuclide therapy with 177Lu-DOTATATE): an emerging option for tumors expressing somatostatin receptors,
• Targeted therapies (sunitinib, everolimus): under investigation in clinical trials.

Chronic medical management with α-blockers (doxazosin, phenoxybenzamine) is indicated in all non-operable cases to control blood pressure, symptoms, and prevent end-organ damage from catecholamine excess.

---

Survival and Prognosis

Pheochromocytoma is historically remembered as the “10% tumor” due to a series of classic “10% rules”:

Note: The “10% rule” is a useful teaching mnemonic, but modern data have revised many of these percentages, particularly the hereditary proportion (now estimated at 30–40%) and the malignancy rate (estimated at 10–17%).

Prognostic Categories

Favorable (90% of cases): Benign pheochromocytoma

• Localized, unilateral, surgically resectable,
• 5-year survival rate > 95%,
• Recurrence rate ~10% (annual surveillance with biochemical testing and imaging required).

Less favorable (10% of cases): Malignant pheochromocytoma

• Defined by the presence of distant metastases (lymph nodes, bones, liver, lungs), histological features alone cannot reliably distinguish benign from malignant.
• 5-year survival rate: 40–60% (variable depending on extent of disease, SDHB mutation status, and treatment options),
• SDHB mutation is associated with the highest malignancy risk (up to 40%).

Long-Term Follow-Up

All patients, including those with apparently benign disease, require lifelong annual surveillance:

• Measurement of plasma or urine catecholamines/metanephrines,
• Periodic imaging (particularly in patients with hereditary syndromes, bilateral disease, or large tumors at initial presentation).

---

Sources and Bibliography

• Cano Megías M, Rodriguez Puyol D, Fernández Rodríguez L, et al. Pheochromocytoma-paraganglioma: Biochemical and genetic diagnosis. Nefrologia. 2016;36(5):481-488.
• Faglia G. Malattie del Sistema Endocrino e del Metabolismo. McGraw-Hill.
• Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942. PubMed
• Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381(6):552-565. PubMed
• Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab. 2007;3(2):92-102. PubMed
• European Network for the Study of Adrenal Tumours (ENSAT) Pheochromocytoma Guidelines